Kopra Bio
Cancer cures via viral immunotherapy
San Francisco, California, US
Kopra Bio is a biotechnology company developing immunotherapies for cancer, specifically for solid tumors, by using genetically engineered viruses that stimulate the immune system.
How We Help
Problem Statement
Current cancer treatments have limited success rates in solid tumors and often target mutations individually. Kopra Bio is developing a therapy that teaches the immune system to kill cancer cells, addressing these limitations.
Core Technology
Genetically engineered viruses
Key Differentiators
Leverages genetically engineered viruses that selectively infect and spread throughout tumors.; Hijacks cancer cells to produce immune signals, recruiting T cells to kill the cancer.; Aims to cure cancer while also eliminating metastasis and recurrence.
Clinical Focus
Immunotherapy
Company Info
- Business Model
- B2B
- Total Funding
- 600,000
- Website
- kopra.bio
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Preclinical: 90% long-term survival in glioblastoma mouse models vs 0% control; Pre-IND stage; QB3 proof-of-concept award for breast, ovarian, colon cancer studies
MedStartr Index Score
?What do you think of Kopra Bio?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.